The pharmaceutical industry has been watching Hikma Pharmaceutical USA Inc. v. Amarin Pharma, Inc. (No. 24-889) closely for its potentially sweeping implications for generic drug competition, as discussed in our prior posts – Supreme Court to Address ‘Skinny Label’ Patent Disputes and Supreme Court Hears Skinny Label Arguments in Hikma v. Amarin, Signaling Impact on Hatch-Waxman Carve-Out Strategy. On June 4, 2026, in a unanimous decision authored by Justice Jackson, the Court reversed the Federal Circuit and held that Amarin failed to plausibly allege that Hikma actively induced infringement of Vascepa’s patented cardiovascular indication through its skinny label, website, patient leaflet, and press releases. The skinny-label carve-out pathway – and the generic industry’s ability to rely on it – emerged intact. The decision builds directly on post-GSK v. Teva1 discussions while adding critical nuance on pleading standards and the limits of “totality of the circumstances” theories.

Brief Recap

Amarin developed Vascepa® (icosapent ethyl), which received FDA approval for severe hypertriglyceridemia (the “SH indication”) in 2012 and, following a landmark $300 million clinical trial, for a second cardiovascular risk reduction indication (the “CV indication”) in 2019 – the latter still covered by in-force patents. Hikma launched a generic version in 2020 under a skinny label approved only for the SH indication, carving out the patented CV indication as permitted under the Hatch-Waxman Section viii framework. Amarin nonetheless sued, alleging that the combination of Hikma’s label, website statements, and press releases – including references to the product as a “generic version of Vascepa®” and citation to Vascepa’s full revenue figures – plausibly established that Hikma had actively encouraged physicians to prescribe the generic for the patented CV use.

Amarin reported Vascepa® sales revenue numbers as follows in its SEC filings:

  • 2019: ~$427.4 million (product revenue, net)
  • 2020: $607.0 million (product revenue, net; record year)
    • Hikma launched generic version Nov. 2020
  • 2021: $580.3 million (product revenue, net)
    • Dr. Reddy’s launched generic version June 2021
  • 2022: $366.5 million (product revenue, net)
    • Apotex and Teva launched generic versions in 2022
  • 2023: $285.3 million (product revenue, net)2
  • 2024: $204.6 million (product revenue, net)
  • 2025: ~$182.8 million (product revenue, net)

The District Court granted Hikma’s motion to dismiss for failure to state a claim, explaining that none of the alleged statements constituted active steps to encourage infringement. The Federal Circuit reversed it in 2024, finding it “at least plausible that a physician could read” the label, website, and press releases “as an instruction or encouragement to prescribe [Hikma’s generic] for any of the approved uses of icosapent ethyl.”3 The Supreme Court granted certiorari and heard arguments on April 29, 2026.

The Decision

The Court framed the key question as follows: “The central question is whether Amarin plausibly alleged that Hikma actively encouraged infringing uses, not merely whether doctors could plausibly read the alleged statements as instructions to infringe.”4

The framing captures where the Federal Circuit went wrong. The appellate court had focused on the receiver’s possible interpretation – what a physician could read into Hikma’s communications. The Supreme Court redirected the inquiry to the sender’s affirmative conduct: did Hikma take active steps to encourage infringement?

The Legal Framework

The Court reaffirmed that a claim under 35 U.S.C. § 271(b)5 requires three elements (1) direct infringement by a third party; (2) knowledge that the induced acts constitute infringement; and (3) “active steps” to encourage that direct infringement.6 The opinion focused on the third element, relying on its prior trio of inducement cases – Grokster7, Global-Tech8, and Limelight9 – to define what “active steps” actually means.

The Court rejected the Federal Circuit’s focus: whether physicians could plausibly read statements as encouragement. Instead, the Court emphasized that active steps require “purposeful, culpable expression and conduct,” as opposed to “ordinary acts incident to product distribution.”10 Critically, the Court denied “mere omissions, inactions, or nonfeasance” as bases to allege active inducement.11

Applying the Standard

Working through Amarin’s allegations category-by-category, the Court found each unpersuasive.

The skinny label itself. The Federal Circuit gave meaningful weight to the fact that Hikma’s label retained information about a clinical study. The Supreme Court dismissed this: “[B]y statute, Hikma’s label must be identical to Amarin’s except for carved-out uses.”12 Compliance with a federal labeling mandate cannot, without more, constitute an affirmative step to induce infringement.

Describing the product as a “generic equivalent.” The Court observed that identifying a product as the generic version of its reference listed drug is “normal industry practice” to “truthfully describe” a generic drug as “‘equivalent’” to the brand-name comparator under the ANDA framework.13 In fact, demonstrating bioequivalence is the very basis on which generic drugs obtain FDA approval. Characterizing standard regulatory language as evidence of inducement would effectively penalize generic manufacturers for complying with the abbreviated approval pathway Congress created.

Omissions. Amarin argued that Hikma’s press releases failed to note that the approved use was limited to the less-known SH indication. The Court rejected this theory, holding that because inducement requires affirmative “statements or actions,” Amarin “may not rely on ‘mere omissions, inactions, or nonfeasance’” to carry its pleading burden.14

The patient information leaflet. The leaflet referenced side effects for individuals with cardiovascular disease and included a general disclaimer that medicines may be prescribed for purposes other than those listed. The Court found these to be “implausibly roundabout ways to induce medical providers to infringe,” far removed from the affirmative encouragement required for inducement under § 271(b).15

Website descriptions and AB rating. Describing the therapeutic category as “hypertriglyceridemia” and noting the drug’s “AB” rating, which indicates that it is therapeutically equivalent to Vascepa when used according to its labeling, “do not plausibly constitute statements designed to ‘stimulate others to commit’ infringement” – particularly where, as here, Hikma’s own website expressly disclaimed that its generic is approved for fewer than all of Vascepa’s indications.16

Press release sales figures. The Court characterized Amarin’s allegation that Hikma’s press releases referenced Vascepa’s sales figures, including those attributable to the patented CV indication, as speculation that such statements, which seemed aimed at investors, could somehow encourage doctors and pharmacists to use its generic for the patented cardiovascular indication. The Court observed that drawing an inference of inducement from these figures requires “a ‘possible’ but not ‘plausible’ chain of events” – the precise threshold between possibility and plausibility that lies at the heart of Iqbal and Twombly.17

The Court reversed the Federal Circuit and remanded for further proceedings consistent with the opinion.

What the Decision Means for Generics

The ruling is a significant win for generic manufacturers and strengthens the skinny-label framework. The Court did not create a categorical exemption from induced infringement for skinny-label generics — liability under § 271(b) remains available where a manufacturer takes affirmative steps to encourage infringing use. But the decision draws a meaningful line between conduct that crosses into active inducement and the ordinary, FDA-mandated, and commercially oriented communications that accompany a generic launch.

For generics contemplating a Section viii carve-out, several practical takeaways emerge:

  • FDA compliance does not immunize a manufacturer from liability, but it is not a basis for liability either. The Court was unwilling to treat federally mandated label content as evidence of infringing intent. Generic manufacturers that operate within the scope of their skinny label approval are not, by that fact alone, exposing themselves to inducement liability.
  • Routine commercial language describing a product as a “generic equivalent” of its reference listed drug will not, without more, support an inducement claim. The ANDA framework is built on bioequivalence — Hikma’s description of its product as a generic version of Vascepa® was, as the Court recognized, a factually accurate description of its regulatory status.
  • Omissions are not affirmative steps. The argument that a generic company must affirmatively call out the limits of its approved indication in every communication — or else risk liability for not doing so — is foreclosed by the Court’s decision. Liability under § 271(b) requires action that encourages infringement, not failure to repeat the boundaries of an FDA-approved skinny label.
  • Vague or speculative chains of inference will not survive a motion to dismiss. The pleading standard under Iqbal18 Twombly19 remains in effect, and Amarin’s attempt to weave a plausible inducement story from product descriptions, sales data, and leaflet language failed to meet it.

The decision should not be read, however, as a green light for careless communication in skinny-label contexts. The Court left open what might constitute active encouragement — and a manufacturer that, for example, explicitly markets its drug to prescribers for a carved-out use, or takes promotional steps directed at the patented indication, would face a very different factual record.

Generics should be careful to 1) adhere to FDA-compliant skinny labels and avoid promotional materials that could be seen as designed to drive the patented use, 2) audit websites, sales training, and responses to medical inquiries for anything beyond neutral facts, 3) be vigilant about product naming/positioning, and 4) train sales and communications personnel against making suggestive statements to physicians.

What the Decision Means for Brands

For branded manufacturers who have invested substantially in developing new indications for existing drugs, the ruling is a setback — but not a total one. Amarin’s position was a compelling one: it spent $300 million to demonstrate that icosapent ethyl reduces cardiovascular events, generated substantial revenue tied to indication-specific sales, and watched a competitor launch a generic that, as the Court acknowledged, would predictably be prescribed off-label for the patented use under state generic-substitution laws.

The Court’s response to that equitable concern was essentially structural rather than legal. The Hatch-Waxman framework, by design, creates this tension, and deliberately balances incentives for pharmaceutical innovation against the goal of timely generic competition. As the Court noted, all 50 states and the District of Columbia have generic substitution laws that permit or require substitution of an AB-rated generic regardless of indication. As a result, off-label use of a skinny-label generic was not merely foreseeable, it was legislatively enabled. However, that dynamic alone does not create § 271(b) liability.

Brands contemplating suing skinny label generic makers will need to think carefully about how to structure their evidence. The decision suggests that brands can still bring viable inducement claims where they can point to genuinely affirmative conduct — promotional materials targeted at a carved-out use, direct communications encouraging physicians to prescribe for the patented indication, implicit suggestions via naming/positioning that go beyond routine equivalence, or other conduct that goes beyond the FDA-mandated labeling and ordinary commercial practices.

The more difficult question — one the Court did not fully answer — is what affirmative conduct, if any, would be sufficient in practice when a generic manufacturer otherwise adheres to an FDA-approved skinny label.  The ruling explicitly notes that implicit encouragement can qualify if “clear to the relevant audience and affirmative” (e.g., suggestive naming in Grokster).

That question is likely to shape the next generation of inducement litigation in the pharmaceutical space.

The decision may also increase lobbying for legislative solutions. Existing proposals such as the Skinny Labels, Big Savings Act seek to further clarify and strengthen protections for Section viii carve-outs. After this decision, innovators will likely feel that the existing framework does not adequately protect the substantial investments required to develop and clinically validate new indications for existing drugs.

Implications for the Biosimilar Context

As noted in our prior posts, Hikma v. Amarin arises under Hatch-Waxman, but its logic is expected to carry over to biosimilar products as well. The Biologics Price Competition and Innovation Act (BPCIA) provides an abbreviated approval pathway for biosimilars and a structured framework for resolving patent disputes between biosimilar sponsors and reference product sponsors. Where a biosimilar is approved for a subset of the reference product’s indications, the breadth of the inducement standard will shape how parties assess the risk of launch communications, indication-specific labeling strategies, and promotional conduct. The Court’s emphasis on affirmative steps — and its rejection of omission-based and inference-based theories — provides useful guidance for biosimilar manufacturers navigating similar carve-out decisions.

Looking Ahead

Hikma v. Amarin is now the leading case on induced infringement in the skinny-label context, and the unanimous opinion provides the clearest articulation of what § 271(b) does and does not require in this setting. The Court’s framework — focusing on the defendant’s affirmative conduct rather than the recipient’s possible interpretation — will guide lower court analysis going forward and shape the risk calculus for both brand and generic manufacturers in future disputes.

The decision also serves as a reminder of the deliberate balance Congress struck in the Hatch-Waxman Act: a system designed to bring generics to market sooner, preserve patent protection for genuinely new uses, and resolve disputes through a defined legal process. We will continue to monitor further developments arising from this decision and its implications across the pharmaceutical and biologics space.

Disclaimer: The information contained in this posting does not, and is not intended to, constitute legal advice or express any opinion to be relied upon legally, for investment purposes or otherwise. If you would like to obtain legal advice relating to the subject matter addressed in this posting, please consult with us or your attorney. The information in this post is also based upon publicly available information, presents opinions, and does not represent in any way whatsoever the opinions or official positions of the entities or individuals referenced herein.        

  1. GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., 7 F. 4th 1320 (2021). ↩︎
  2. Since 2023, the FDA has approved at least seven other generic versions. ↩︎
  3. Amarin Pharma, Inc. v. Hikma Pharms. USA Inc.,104 F. 4th 1370, 1378-80 (Fed. Cir. 2024). ↩︎
  4. Slip op. at 2. ↩︎
  5. “Whoever actively induces infringement of a patent shall be liable as an infringer.” ↩︎
  6. Slip op. at 2. ↩︎
  7. Metro Goldwyn Mayer Studios Inc. v. Grokster, Ltd., 545 U.S. 913 (2005). ↩︎
  8. Global-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754 (2011). ↩︎
  9. Limelight Networks, Inc. v. Akamai Technologies, Inc., 572 U. S. 915 (2014). ↩︎
  10. Slip op. at 2. ↩︎
  11. Id. at 3. ↩︎
  12. Id. at 3. ↩︎
  13. Id. at .11 ↩︎
  14. Id. at 3. ↩︎
  15. Id. at 3. ↩︎
  16. Id. at 3. ↩︎
  17. Id. at 3. ↩︎
  18. Ashcroft v. Iqbal, 556 U. S. 662, 678 (2009). ↩︎
  19. Bell Atlantic Corp. v. Twombly, 550 U. S. 544, 570 (2007). ↩︎